Member Info for DugWalker

They are activist investors with a history of taking large holdingsbin distressed companies in order to force change in management strategy. I see them buying in as a vote of no confidence in Ross however an activist shareholder could finally force OBD to do what it should have been doing 2-3 years ago. Potentially good news.

Seems to me that much of the criticism levelled at Routh is borne of dissatisfaction with the SP rather than a reflection of operational realities. It is also a little hypocritical to simultaneously complain about lack of communication whilst using said communications as evidence of non-performance. I agree that it is frustrating to find deadlines repeatedly missed, and I have said that MR needs to discover the art of underpromising and overdelivering, however the fact is we are not the operators of our key assets and have zero control over much that he is being blamed for.

What we are hearing from Heyco and Po Valley is that we will be drilling new wells in the near term future and I see no reason to disbelieve that. What we don't need is fellow shareholders talking the SP down further. Its like a self harming society in here recently.

Its been a long time coming but a little patience should see revenues rocket as wells start coming non stream over the next 12 months. Everything else is noise and is counterproductive to what posters want to see, namely a steady increase in the SP towards a realistic valuation of the company.

@ ShaquileOatmeal.

You ard correct I screwed up Viura calcs. Should be about £1.5 million p.a. to Prospex now, potentially increasing to about £5 million p.a. if I assume similar flow rates from the 2 new wells planned by end 2026. Nevertheless the basic point remains. If all planned wells meet expectations we will soon see circa 12 million p.a. from Italy plus about £5 million from Viura and a couple of million from Spain. Annual revenues will match or exceed current mcap depending on forward gas prices. Bottom line is still that PXEN is way undervalued at this share price.

Company is grossly undervalued with current annual revenues (about £12 million p.a. from Viura and £3 million p.a. from Italy) just about equal to the mcap. Italy set to become 12 to 15 million per annum and Viura likely to double all within avq2-18 month timeline. 40 million per annum revenues, mostly profit at the current mcap sees the share price rocket or the company gets bought out.

Which will of course see our revenues from Italy grow correspondingly.

https://www.cruxinvestor.com/posts/italian-gas-producer-targets-4-5x-growth-in-europes-premium-pricing-environment

The Oct 24 RNS announced that PXEN had qualified to submit applications (after scrutiny by the Polish regulators). It DID NOT say applications had been submitted. It was just the first step of several towards that goal.

Todays's news on VIURA flows should see us bring in £10-12 million revenue, from this well alone, by the end of the financial year (end March 2026). This is whilst we have our initial capital investment repaid. Thereafter it will increase revenues by about £1 million per month.

Compare to current mcap!

The same talk they told us were ongoing under the previous CEO. They are full of bull.

None are validated to levels acceptable for widespread use by the health industries.

Validation costs will be significant and big pharma will assess the risk reward relative to their own portfolio of emerging products. Many will be happy to watch them go bust thrn.pick.up the IP for a song.

Typical of their hyperbolicly inflated claims. We were told 18-24 months ago to , for example, expect commercial agreements in the vetrinary sector. Where are they?

Great science, potentially great tests. Clueless on commercialisation.

Nonsense Panman. Tjis test does not become the basis for a national screening trial unless and until it is fully validated.

Good to see moves to further grow assets and prospective resources. Broker notes tend to heavily discount assets begore the come online. If the drilling programme planned for the coming 1-2 years is even.moderately successful OBD is set for very significant growth of assets and revenues. Broker notes valuing the company at 20p will soon be a distant memory. Routh has already said that he would need to see bids of 'many multiples' of single digit share prices to even consider selling up.

Getting a mention in an update about national screening trial is a million miles from inclusion or participation in said trials. Large scale trials incorporating a wide range of ethnicities and ages is a mandatory requirement for a test like PSE to gain medical approval and qualify for large commercial contracts. OBD is still basing its lab validation claims on the cohort of roughly 200 patients (194 if memory serves). Compare this with the numbers involved in the Galleri blood test recently featured in the news.

The Largest Study of a Multi-Cancer Early Detection Blood Test https://share.google/T8DpYA63udBRTVEuW

Quite a contrast. How will OBD finance the necessary trials so they can start pursuing contracts with acceptable medical evidence of efficacy?

Initial impression is the recommendations are relatively benign but require the industry as a whole to upgrade self regulation. Doubt it contains many surprises, for example.the requirement to publish prices for prescribed drugs and routine services has long been anticipated.

The big thing is that the market uncertainty is greatly reduced by virtue of this much delayed report. Perhaps we will start to see the share price recover to more realistic levels as a result.

The manufacturer reports an overall sensitivity of 94% and a specificity of 97%, suggesting strong potential

Note:

1. "The manufacturer reports" = This needs proper validation.

2. "Suggests strong potential" = It isnt ready for use.

Sunak is an ambassador for prostate cancer technologies and will have visited under those auspices. Dodds is the local MP and will have visited at the invite of OBD. I can't find any other information about 'high profile' politicians going there. Politicians visited companies on a daily basis. It rarely means anything other than they want to maintain their 'high profile'.

PSE is NOT being considered for an NHS contract!

A National screening programme for prostate is all that is being considered. The candidate technologies and tests are currently being assessed under the auspices of the Transform project. PSE is not one of the tests being assessed though other blood tests are.

PSE needs to be validated against a cohort of tens of thousands with a wide genetic pool before it would be considered for adoption by the NHS. OBD could have done this by participating in Transform, but they chose not to. They don't have the finances or resources to undertake the necessary validation tests on their own.

Those are the hard facts of the matter.

NHS contracts are a pipedream.

I think you need to rely read the RNS yourself. Perhaps post the bit announcing the NHS contracts you seem to think are imminent.

Its an RNS full of half truths and inferences. Nothing more than marketing on behalf of the share price and a likely placing.

Read this.

NHS England » NHS England and NICE genomic testing pathway https://share.google/it9Nij6nm3FJleTdl

Then email Ross and ask him which stage OBD has reached in this approval process.

There is zero chance of NHS contracts for PSE.

ZERO

Do some research for goodness sakes. All the information you need is out there.